Evan Lippman - 04 Mar 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
EVP, Business Development
Signature
/s/ Dov Bergwerk as attorney-in-fact for Evan Lippman
Issuer symbol
TEVA
Transactions as of
04 Mar 2026
Net transactions value
$0
Form type
4
Filing time
06 Mar 2026, 16:11:33 UTC
Previous filing
19 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lippman Evan EVP, Business Development C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL /s/ Dov Bergwerk as attorney-in-fact for Evan Lippman 06 Mar 2026 0002062834

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Award +27,347 $0.000000* 27,347 04 Mar 2026 Ordinary Shares 27,347 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2 Restricted share units were granted on March 4, 2026, with 6,836 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 6,839 vesting on March 4, 2030.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.